STOCK TITAN

Teva Pharmaceutical Industries Limited American Depositary Shares - $TEVA STOCK NEWS

Welcome to our dedicated page for Teva Pharmaceutical Industries American Depositary Shares news (Ticker: $TEVA), a resource for investors and traders seeking the latest updates and insights on Teva Pharmaceutical Industries American Depositary Shares stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Teva Pharmaceutical Industries American Depositary Shares's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Teva Pharmaceutical Industries American Depositary Shares's position in the market.

Rhea-AI Summary

Teva Pharmaceutical Industries announced that Richard Francis, Teva's President and CEO, will present at the 2024 Bank of America Healthcare Conference on May 14, 2024. The presentation will be available via live webcast on Teva’s Investor Relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.71%
Tags
conferences
-
Rhea-AI Summary

Teva Pharmaceutical Industries released its 2023 Healthy Future Report, outlining a renewed sustainability strategy focused on achieving net zero emissions, renewable electricity, and health system strengthening. The report highlights the issuance of $2.49 billion in sustainability-linked bonds, bringing the total to $7.5 billion, making Teva the largest issuer in pharmaceuticals globally. Teva's efforts in access to medicines, greenhouse gas emission reductions, supplier engagement, and community support are detailed. The report reflects Teva's commitment to sustainability, business integrity, and social responsibility.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.72%
Tags
none
-
Rhea-AI Summary
Teva Pharmaceuticals presents final results from the Phase 4 START study at the 2024 AAN Annual Meeting, confirming the effectiveness, safety, adherence, and patient satisfaction with the 4-week Titration Kit for AUSTEDO in treating Huntington's disease chorea.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.06%
Tags
none
Rhea-AI Summary
Teva Pharmaceuticals' AJOVY shows efficacy in Phase 3 study, reducing migraine days significantly. The drug met primary and secondary endpoints, demonstrating superior efficacy over placebo. AJOVY also displayed a favorable safety profile. The study targeted adult Chinese patients, with positive results indicating potential global impact.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.14%
Tags
-
Rhea-AI Summary
Teva Pharmaceutical Industries (TEVA) will release its first quarter 2024 financial results on May 8, 2024, followed by a conference call and webcast. Participants can register in advance for the call and access the webcast on Teva's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.86%
Tags
conferences earnings
-
Rhea-AI Summary
Teva Pharmaceuticals presents data on UZEDY, an extended-release injectable suspension of risperidone, for the treatment of schizophrenia in adults. The data includes insights on dosing conversions and strategies for switching from a long-acting injectable formulation. The presentation at the SIRS 2024 Congress highlights the efficacy and safety profile of UZEDY, emphasizing its potential to reduce relapse rates and hospitalizations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Teva Pharmaceuticals and mAbxience collaborate on a biosimilar candidate for oncology treatment, aiming to provide cost-effective alternatives globally. The partnership supports Teva's growth strategy and mAbxience's expansion plans, emphasizing a commitment to improving healthcare access.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.35%
Tags
none
-
Rhea-AI Summary
Teva Pharmaceutical Industries and Launch Therapeutics collaborate to advance Teva's Dual-Action Asthma Rescue Inhaler program TEV-‘248, with a strategic funding agreement of up to $150 million. The program aims to be the first ICS-SABA for both adult and pediatric asthma indications, combining fluticasone propionate and albuterol sulfate.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.09%
Tags
none
-
Rhea-AI Summary
Teva Pharmaceutical Industries Ltd. forms a partnership with Jiangsu Nhwa Pharmaceutical Co., Ltd. to market and distribute AUSTEDO for neurodegenerative and movement disorders in China. AUSTEDO, a deuterated drug, targets chorea associated with Huntington’s disease and tardive dyskinesia, offering innovative treatment options. The partnership aims to enhance patient access to AUSTEDO in China's neuro-psychiatric health sector, leveraging Nhwa's expertise.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.1%
Tags
partnership
Rhea-AI Summary
Teva Pharmaceuticals announces positive safety and tolerability data for anti-TL1A (TEV-'574) in inflammatory bowel disease, demonstrating rapid and sustained suppression of free TL1A. The asset shows a well-tolerated safety profile and supports ongoing Phase 2b clinical investigation. Teva also disclosed a collaboration deal with Sanofi for co-development and co-commercialization of anti-TL1A (TEV-'574) for UC and CD, with significant financial implications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.45%
Tags
none
Teva Pharmaceutical Industries Limited American Depositary Shares

NYSE:TEVA

TEVA Rankings

TEVA Stock Data

15.80B
1.12B
53.13%
1.03%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
PETACH TIKVA

About TEVA

Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company with headquarters in Tel Aviv, Israel. It specializes primarily in generic drugs, but other business interests include active pharmaceutical ingredients and, to a lesser extent, proprietary pharmaceuticals.